Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Withdrawn1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

withdrawn133%
terminated133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
unknown

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)

NCT04453839
terminatedphase_2

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

NCT04360096
withdrawnphase_3

Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19

NCT05137795

Clinical Trials (3)

Showing 3 of 3 trials
NCT04453839

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)

Unknown
NCT04360096Phase 2

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

Terminated
NCT05137795Phase 3

Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3